![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB | |
![[img]](http://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Materials)
2MB |
| Item Type: | Article |
|---|---|
| Title: | Frequency and predictors of relapses following SARS-CoV-2 vaccination in patients with multiple sclerosis: interim results from a longitudinal observational study |
| Creators Name: | Frahm, N. and Fneish, F. and Ellenberger, D. and Haas, J. and Löbermann, M. and Peters, M. and Pöhlau, D. and Röper, A.L. and Schilling, S. and Stahmann, A. and Temmes, H. and Paul, F. and Zettl, U.K. |
| Abstract: | Despite protection from severe COVID-19 courses through vaccinations, some people with multiple sclerosis (PwMS) are vaccination-hesitant due to fear of post-vaccination side effects/increased disease activity. The aim was to reveal the frequency and predictors of post-SARS-CoV-2-vaccination relapses in PwMS. This prospective, observational study was conducted as a longitudinal Germany-wide online survey (baseline survey and two follow-ups). Inclusion criteria were age ≥18 years, MS diagnosis, and ≥1 SARS-CoV-2 vaccination. Patient-reported data included socio-demographics, MS-related data, and post-vaccination phenomena. Annualized relapse rates (ARRs) of the study cohort and reference cohorts from the German MS Registry were compared pre- and post-vaccination. Post-vaccination relapses were reported by 9.3% PwMS (247/2661). The study cohort’s post-vaccination ARR was 0.189 (95% CI: 0.167–0.213). The ARR of a matched unvaccinated reference group from 2020 was 0.147 (0.129–0.167). Another reference cohort of vaccinated PwMS showed no indication of increased post-vaccination relapse activity (0.116; 0.088–0.151) compared to pre-vaccination (0.109; 0.084–0.138). Predictors of post-vaccination relapses (study cohort) were missing immunotherapy (OR = 2.09; 1.55–2.79; p < 0.001) and shorter time from the last pre-vaccination relapse to the first vaccination (OR = 0.87; 0.83–0.91; p < 0.001). Data on disease activity of the study cohort in the temporal context are expected for the third follow-up. |
| Keywords: | SARS-CoV-2, COVID-19, Vaccination, Multiple Sclerosis, Relapse |
| Source: | Journal of Clinical Medicine |
| ISSN: | 2077-0383 |
| Publisher: | MDPI |
| Volume: | 12 |
| Number: | 11 |
| Page Range: | 3640 |
| Date: | 24 May 2023 |
| Official Publication: | https://doi.org/10.3390/jcm12113640 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
